When doctors detect elevated levels of SerpinB3 in a blood test, it can signal that something is seriously wrong, from hard-to-treat cancers to severe inflammatory conditions.

SerpinB3 is a critical protein that often reveals when the body’s barrier tissues, like the skin or lungs, are under serious stress from cancer or chronic illness.

A vaccine that tackles the bacteria that cause up to 200 million childhood infections every year could be possible, experts say.

In the first study of its kind, an international team including those at the Wellcome Sanger Institute, the University of Oslo, the University of Oxford and the Shoklo Malaria Research Unit at Mahidol University in Thailand, analysed new and existing Haemophilus influenzae (H. influenzae) genomes, from global samples collected between 1962-2023.

A research team led by the Medical University of Vienna, the HUN-REN Research Centre for Natural Sciences and the Eötvös Loránd University in Budapest has developed a groundbreaking new chemotherapeutic agent, LiPyDau, which shows remarkable efficacy against multiple tumor types in preclinical studies. Published in the leading journal Molecular Cancer, the study introduces a highly promising strategy for tackling drug-resistant cancers.

While ingestible capsule endoscopes have revolutionized digestive tract diagnosis, current capsule devices are still difficult to combine diagnostic functions (targeted biopsy) and therapeutic functions (targeted drug delivery) in one-time oral intake. Now, research has broken through this limitation by presenting a novel multichamber magnetic capsule robot (named macabot) that can selectively open specific chambers on demand for targeted liquid sampling or targeted drug release.

Three new Cochrane reviews find evidence that GLP-1 drugs result in clinically meaningful weight loss, but industry-funded studies raise questions. The reviews were commissioned by the World Health Organization (WHO) to inform upcoming guidelines on the use of these drugs to treat obesity.

The reviews, which examine the effects of three weight loss drugs known as GLP-1 receptor antagonists, have found that all three drugs result in clinically meaningful weight loss compared with placebo.

The activation and deactivation of apoptosis is a promising field of research in basic biomedical research. The team led by Prof. Franz Hagn from the Chair of Structural Membrane Biochemistry at the TUM School of Natural Sciences has now discovered a new switch: "Many research teams worldwide are working on the exciting topic of apoptosis and its targeted control. The big advantage is that we are dealing with a highly efficient, evolutionarily developed regulatory mechanism. So, we don't have to invent something completely new, but can use the appropriate structural methods to learn from nature's optimized processes."

Pfizer Inc. today announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of Chancery. The lawsuit asserts claims for breach of contract, breach of fiduciary duty, and tortious interference in contract arising from Metsera’s breach of its obligations under the merger agreement between Pfizer and Metsera.

Pfizer Inc. (NYSE: PFE) today announced the U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), with respect to Pfizer’s pending acquisition of Metsera (NASDAQ: MTSR).

The termination of the waiting period under the HSR Act satisfies the regulatory review requirements under the previously announced proposed acquisition of Metsera, which was set to expire on November 7.